Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.59 |
| ▸ | HPGD | P15428 | 4/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.59 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.59 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.59 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.50 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 3/20 | 0.44 |
| ▸ | CA2 | P00918 | 3/20 | 0.44 |
| ▸ | CA12 | O43570 | 2/20 | 0.44 |
| ▸ | CA7 | P43166 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7880047 | 0.88 | KDM4E (0.49) | KDM4EALDH1A1HPGDHSD17B10SMN1; SMN2 | |
| SCHEMBL26119911 | 0.83 | MAPK11 (0.53) | KDM4EALDH1A1HPGDHSD17B10SMN1; SMN2 | |
| SCHEMBL31636989 | 0.82 | MAPK11 (0.56) | KDM4EALDH1A1HPGDHSD17B10SMN1; SMN2 | |
| SCHEMBL231079 | 0.81 | MAPK11 (0.55) | KDM4EALDH1A1HPGDHSD17B10SMN1; SMN2 | |
| SCHEMBL16595838 | 0.80 | MAPK14 (0.48) | KDM4EALDH1A1HPGDHSD17B10SMN1; SMN2 | |
| SCHEMBL30623233 | 0.80 | KDM4E (0.56) | KDM4EALDH1A1HPGDHSD17B10SMN1; SMN2 | |
| SCHEMBL232145 | 0.80 | KDM4E (0.56) | KDM4EALDH1A1HPGDHSD17B10SMN1; SMN2 | |
| SCHEMBL27736579 | 0.80 | KDM4E (0.56) | KDM4EALDH1A1HPGDHSD17B10SMN1; SMN2 | |
| SCHEMBL29343021 | 0.78 | KDM4E (0.69) | KDM4EALDH1A1HPGDHSD17B10SMN1; SMN2 | |
| SCHEMBL22489748 | 0.78 | KDM4E (0.54) | KDM4EALDH1A1HPGDHSD17B10SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8778928-B2 | Indolyl-oxadiazolyl-diazabicyclononane derivatives and their medical and diagnostical use | DANPET AB (SE) | 2014-07-15 | — | — | US | disclosed |
| US-8211904-B2 | Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease | Merck, Sharp & Dohme Corp. (US) | 2012-07-03 | — | — | US | disclosed |
| EP-1910364-B1 | SPIROPIPERIDINE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | MERCK SHARP & DOHME (US) | 2012-03-21 | — | — | EP | disclosed |
| US-20120003153-A1 | NOVEL INDOLYL-OXADIAZOLYL-DIAZABICYCLONONANE DERIVATIVES AND THEIR MEDICAL AND DIAGNOSTICAL USE | NEUROSEARCH A/S (DK) | 2012-01-05 | — | — | US | disclosed |
| CN-102300574-A | Novel indolyl-oxadiazolyl-diazabicyclononane derivatives and their medical and diagnostical use | — | 2011-12-28 | — | — | CN | disclosed |
| EP-1910364-A2 | SPIROPIPERIDINE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | Merck & Co., Inc. (US) | 2008-04-16 | — | — | EP | disclosed |
| WO-2007011833-A2 | SPIROPIPERIDINE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | MERCK & CO., INC. (US) | 2007-01-25 | — | — | WO | disclosed |
| US-20070021454-A1 | Spiropiperidine beta-secretase inhibitors for the treatment of Alzheimer's disease | MERCK SHARP & DOHME LLC | 2007-01-25 | — | — | US | disclosed |
| EP-0915872-B1 | SUBSTITUTED BISINDOLYLMALEIMIDES FOR THE INHIBITION OF CELL PROLIFERATION | HOFFMANN LA ROCHE (CH) | 2003-05-14 | — | — | EP | disclosed |
| US-6030994-A | ANTIPROLIFERATIVE, TUMOR AND CARCINOGENIC AGENTS; PARTICULARLY FOR TREATMENT OF SOLID TUMORS AND THOSE OF THE BREAST AND COLON | HOFFMANN-LA ROCHE INC. (US) | 2000-02-29 | — | — | US | disclosed |
| US-5856517-A | ANTIPROLIFERATIVE AGENTS USEFUL IN THE TREATMENT OF CANCER. | HOFFMANN-LA ROCHE INC. (US) | 1999-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021454-A1 | Spiropiperidine beta-secretase inhibitors for the treatment of Alzheimer's disease | BACE1, APP, PSEN1 | KDM4E 3699/4885ALDH1A1 717/4885HPGD 825/4885 |
| US-20120003153-A1 | NOVEL INDOLYL-OXADIAZOLYL-DIAZABICYCLONONANE DERIVATIVES AND THEIR MEDICAL AND DIAGNOSTICAL USE | CHRNA6, CHRNA10, CHRNA3 | KDM4E 2986/4885ALDH1A1 1114/4885HPGD 713/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.